Baldwin R M, Wu J L
Medi-Physics, Inc., Emeryville CA 94608.
J Nucl Med. 1988 Jan;29(1):122-4.
Application of chemical methods for characterizing the in vivo behavior of iofetamine HCI 123I (IMP) has shed light on the metabolism of iofetamine in animals and humans. A successful technique consists of ethyl acetate extraction of the metabolites from tissue samples acidified with perchloric acid, separation of the mixture by high performance liquid chromatography, and quantitation of the radioactive components with a sensitive scintillation detector. Metabolism of iofetamine HCI 123I proceeds sequentially from the N-isopropyl group on the amphetamine side chain. The first step, dealkylation to the primary amine p-iodoamphetamine (PIA), occurs readily in the brain, lungs, and liver; activity in the brain and lungs consists of only IMP and PIA even 24 hr after administration. The rate-limiting step appears to be deamination to give the transitory intermediate p-iodophenylacetone, which is rapidly degraded to p-iodobenzoic acid and conjugated with glycine in the liver to give the end product of metabolism, p-iodohippuric acid, which is excreted through the kidneys in the urine.
应用化学方法表征盐酸碘苯丙胺123I(IMP)的体内行为,为碘苯丙胺在动物和人体内的代谢情况提供了线索。一种成功的技术包括用乙酸乙酯从用高氯酸酸化的组织样品中提取代谢物,通过高效液相色谱法分离混合物,并用灵敏的闪烁探测器对放射性成分进行定量。盐酸碘苯丙胺123I的代谢从苯丙胺侧链上的N-异丙基依次进行。第一步,脱烷基生成伯胺对碘苯丙胺(PIA),这在脑、肺和肝脏中很容易发生;即使在给药24小时后,脑和肺中的活性成分也仅为IMP和PIA。限速步骤似乎是脱氨生成短暂的中间体对碘苯丙酮,其迅速降解为对碘苯甲酸,并在肝脏中与甘氨酸结合生成代谢终产物对碘马尿酸,后者通过肾脏随尿液排出。